All In Biotech

Drug Trial Radar · NCT07881991

Phase 2 Study of SYH2066 Tablets Compared With Placebo in Chinese Adult Patients With Respiratory Syncytial Virus Infection.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of SYH2066 Tablets in Adult Participants With Respiratory Syncytial Virus Infection.

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Nov 13, 2026

Primary completion

Dec 31, 2027

Study completion Mar 31, 2028

Sponsor

Sponsor type
Industry
First posted
Oct 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic profile of SYH2066 tablets in adult patients with RSV infection. Approximately 80 adult patients with RSV infection are expected to be enrolled and assigned to three active treatment groups and one placebo group, with approximately 20 eligible participants per group. The study consists of a 3-day screening period, a 5-day treatment period, and an 8- to 10-day follow-up period. Throughout the study, safety assessments, PK blood sampling, nasopharyngeal (NP) swab collection, and RSV symptom recording will be performed

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

  • SYH2066Drug

    Protocol-specified dose of SYH2066 tablets administered orally for 5 days.

  • PlaceboDrug

    Protocol-specified dose of placebo tablets administered orally for 5 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the curve (AUC) of RSV RNA viral load measured by RT-qPCR in nasopharyngeal swab samplesTime frame: Up to Day 14

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.